Compare
Xeris Biopharma Holdings, Inc. vs Evolus, Inc. vs CorMedix Inc. vs Harrow, Inc.
| Latest fiscal year | Xeris Biopharma Holdings, Inc. XERS | Evolus, Inc. EOLS | CorMedix Inc. CRMD | Harrow, Inc. HROW |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $291.85M | $297.18M | $311.71M | $272.30M |
| Revenue growth (YoY) | +43.7% | +11.6% | +617.0% | +36.4% |
| Gross margin | n/a | 66.3% | 88.5% | 75.1% |
| Operating margin | 8.5% | -11.0% | 48.2% | 11.2% |
| Net margin | 0.2% | -17.4% | 52.3% | -1.9% |
| Net income | $554.0K | -$51.64M | $163.06M | -$5.14M |
| EPS (Diluted) | $0.00 | -$0.80 | $2.04 | -$0.14 |
| Operating cash flow | $28.63M | -$42.27M | $175.05M | $43.86M |
| Free cash flow | n/a | -$45.71M | $172.79M | $42.98M |
| Cash & equivalents | $111.04M | $53.83M | $144.84M | $72.93M |
| Total assets | $383.53M | $225.87M | $826.14M | $399.48M |
| Total liabilities | $369.84M | $248.97M | $420.83M | $347.39M |
| Shareholders' equity | $13.69M | -$23.11M | $405.31M | $52.45M |
| Return on year-end equity | 4.0% | n/a | 40.2% | -9.8% |
| Shares outstanding | 166.22M | 65.01M | 79.26M | 37.23M |
Revenue, most recent five fiscal years
| Fiscal year | Xeris Biopharma Holdings, Inc. | Evolus, Inc. | CorMedix Inc. | Harrow, Inc. |
|---|---|---|---|---|
| Latest | $291.85M Ended 2025-12-31 | $297.18M Ended 2025-12-31 | $311.71M Ended 2025-12-31 | $272.30M Ended 2025-12-31 |
| 1 year earlier | $203.07M Ended 2024-12-31 | $266.27M Ended 2024-12-31 | $43.47M Ended 2024-12-31 | $199.61M Ended 2024-12-31 |
| 2 years earlier | $163.91M Ended 2023-12-31 | $202.09M Ended 2023-12-31 | n/a | $130.19M Ended 2023-12-31 |
| 3 years earlier | $110.25M Ended 2022-12-31 | $148.62M Ended 2022-12-31 | $65.4K Ended 2022-12-31 | $88.59M Ended 2022-12-31 |
| 4 years earlier | $49.59M Ended 2021-12-31 | $99.67M Ended 2021-12-31 | $190.9K Ended 2021-12-31 | $72.48M Ended 2021-12-31 |